This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This EBI3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 153-181 amino acids from the C-terminal region of human EBI3.
IL-27b
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
WB: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Haltbarkeit
6 months
Kempe, Heinz, Kokai, Devergne, Marx, Wirth: "Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques." in: The American journal of pathology, Vol. 175, Issue 1, pp. 440-7, (2009) (PubMed).
Krumbiegel, Anthogalidis-Voss, Markus, Zepp, Meyer: "Enhanced expression of IL-27 mRNA in human newborns." in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, Vol. 19, Issue 6, pp. 513-6, (2008) (PubMed).
Poleganov, Bachmann, Pfeilschifter, Mühl: "Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor." in: Molecular immunology, Vol. 45, Issue 10, pp. 2869-80, (2008) (PubMed).
Carl, Bai: "IL27: its roles in the induction and inhibition of inflammation." in: International journal of clinical and experimental pathology, Vol. 1, Issue 2, pp. 117-23, (2008) (PubMed).
This gene was identified by its induced expression in B lymphocytes in response Epstein-Barr virus infection. It encodes a secreted glycoprotein belonging to the hematopoietin receptor family, and heterodimerizes with a 28 kDa protein to form interleukin 27 (IL-27). IL-27 regulates T cell and inflammatory responses, in part by activating the Jak/STAT pathway of CD4+ T cells.